AzTrials
AzTrials

Substance DependenceNCT03000699

Efficacy of Cognitive Bias Modification in Residential Treatment for Addiction

A study testing Cognitive Bias Modification in people with Substance Dependence, run by Centre for Addiction and Mental Health at 1 site in Canada.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record
Search all trials

Trial summary

The purpose of this study is to determine whether computer bias modification for interpretation bias (CBM-I) is effective in the reduction of suicidal ideation in substance use disorders. Read more about this study

Who is it for?
Ages 18 years and older
Conditions the study is for
Substance Dependence
What is being tested?
Cognitive Bias Modification
Could I receive a placebo?
No, everyone receives an active treatment
How many people
88 participants
Where
1 siteCanada
Study dates
1 Mar 2017to 31 Dec 2018
Phase
Interventional
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 years and older
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Who may be able to join

  • Exhibit moderate suicide risk or greater
  • Be enrolled in the Addictions Services inpatient program
  • Fluent in reading English
  • Capacity to give informed consent

Who cannot join

  • A lifetime diagnosis of a psychotic or bipolar disorder
  • Significant neurological disorder or psychical illness likely to interfere with participation
  • Psychotropic medication changes within the past two weeks

Trial locations and contacts

1 site in 1 country.

Canada1 site
  • Centre for Addiction and Mental Health

    Toronto, Ontario, M5T 1R8

Other trials in Canada

About this study

The purpose of this study is to determine whether computer bias modification for interpretation bias (CBM-I) is effective in the reduction of suicidal ideation in substance use disorders.

Read the detailed description

Eighty-eight adult inpatients completing residential treatment in the Addictions Services at the Centre for Addiction and Mental Health (CAMH) will be randomized to receive CBM-I daily for one week, adjunct to the residential psychosocial treatment or to an assessment-only control condition. Participants will complete clinical measures consisting of interviews and questionnaires measuring suicidal ideation, hopelessness, depression, negative affect, and interpretation biases before, during and after treatment.

Being tested
Cognitive Bias Modification
Keywords
cognitive bias modification, interpretation bias, suicidal ideation, depression
Medical subject headings
Substance-Related Disorders, Suicidal Ideation, Depression

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • Cognitive Bias ModificationBehavioural

    Training paragraphs describe scenarios designed to be ambiguous at the outset and to resolve in a positive direction, with the intention of establishing a learning contingency between the ambiguity at the beginning of the scenario and the positive resolution that becomes clear towards the end of the statement.

Study groups in NCT03000699
Study groupRoleWhat they receive
Cognitive Bias ModificationExperimental64 training paragraphs, approximately 10-20 seconds each, digitally recorded and presented stereophonically through headphones, delivered over the course of one week.
Receives: Behavioral: Cognitive Bias Modification
Assessment-Only ControlNo interventionNo training will be provided.

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Columbia-Suicide Severity Rating Scale, Screen Version (C-SSRS)

    This scale quantifies the severity of suicidal ideation and behaviour.

    Measured: Seven days

Secondary outcomes (4)
  1. Beck Hopelessness Scale (BHS)

    This questionnaire assesses thoughts and emotions associated with the future.

    Measured: Seven days

  2. Beck Depression Inventory II (BDI-II)

    This questionnaire assesses severity of depressive symptoms and cognitions.

    Measured: Seven days

  3. Positive and Negative Affect Schedule (PANAS)

    This questionnaire assesses current positive and negative mood

    Measured: Seven days

  4. Scrambled Sentences Tests

    This computer test will be used as an implicit measure of negative interpretation bias.

    Measured: Seven days

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted22 Dec 2016 (estimated)
  2. Study start1 Mar 2017
  3. Primary completion1 Oct 2018
  4. Study completion31 Dec 2018

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase N/A
Primary purpose
Treatment
Allocation
Randomised
Intervention model
Parallel groups
Masking
Single blind
Who is masked
Outcomes assessor
Enrolment
88 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT03000699
Sponsor's protocol ID
077/2016
Status last verified
Jan 2019
First submitted
20 Dec 2016
Last updated
30 Jan 2019
Results posted
No
Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
No

Questions about this trial

What is this clinical trial studying?

A study testing Cognitive Bias Modification in people with Substance Dependence, run by Centre for Addiction and Mental Health at 1 site in Canada.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 4 inclusion and 3 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 30 Jan 2019. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in Canada. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Columbia-Suicide Severity Rating Scale, Screen Version (C-SSRS) (time frame: Seven days). It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 30 Jan 2019.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in